HR Execs on the Move


 
We created the first FDA-cleared app-enabled thermometer because, from our work in the health systems within the U.S. and across impoverished nations throughout the world, we`ve learned that an elevated temperature is often the first sign of sickness. By building intelligence into a once basic thermometer and turning it into a connected device, we`re able to keep an eye on illnesses from beginning to end. We can more quickly alert users when fever and symptoms warrant closer monitoring or a visit to the doctor. Our network of connected thermometers can even offer helpful insights such as common illnesses that may be ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.kinsahealth.com
  • 535 Mission St 18th Floor
    San Francisco, CA USA 94105
  • Phone: 415.236.4811

Executives

Name Title Contact Details
Erin Koehler
Chief Strategy & Product Officer Profile

Similar Companies

Awair

Our mission at Awair is to empower you with the knowledge, motivation, and confidence to be healthy and thrive in your environment.

Oscor

OSCOR Inc. designs, develops, manufactures and markets a variety of highly specialized implantable cardiac pacing leads, venous access systems and diagnostic catheters. Oscor is also leveraging its proprietary lead technologies toward the development

ClaimPay

Claimpay is a healthcare billing company that combines smart technology with billing expertise to manage a practices entire revenue process.

Electra-Med Corp

Electra-Med Corp is a Flint, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Ovid Therapeutics

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.